HOUSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the ...

In this video, Adriana Rossi, MD, assistant professor of medicine at Mount Sinai, highlights upcoming clinical trials in multiple myeloma.

Qihan Biotech receives US FDA’s IND clearance for a universal dual-target CAR-T candidate, QT-019C: Hangzhou, China Friday, May 22, 2026, 12:00 Hrs [IST] Qihan Biotech, a clinic ...

Oncotarget recently published "Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy" which reported that Chimeric ...

In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin ...

AFNT-211: An FAS-41BB–enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...

Oncotarget recently published "Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy" which reported that Chimeric ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Bendamustine lymphodepletion resulted in significant CAR T-cell expansion among patients with ...

Qihan Biotech, a biotechnology company dedicated to applying high-throughput, multiplexed gene editing technologies to cell therapy and organ transplantation, announced today that QT-019C has received ...

A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II ...